918博天堂(中华区)官方网站

In 2021, Huaota had 4 projects in preparation for clinical research application (IND), including HB0028 (PD-L1/TGF-β), HB0036 (PD-L1/TIGIT), HB0030 (TIGIT), HB0034 (IL-36R). At present, Huaota has more than 20 ongoing projects, 7 of which have been in clinical study stage around the world. HB0025 (the first bispecific fusion protein targeting PD-L1/VEGF in clinical research) is in Phase I clinical trials in both the United States and China; Phase I clinical trial of HB0017 (a total of 3 indications for autoimmune diseases) had been finished in New Zealand and Phase II has been initiated in China; HOT-1030 (CD137) is in Phase II clinical research; HB002.1T (solid tumor) and HB002.1M (fundus lesions), both of which share the structure of VEGF-FC fusion protein, is in Phase II for different indications. Huaota commits to develop, manufacture innovative drugs in the field of oncology, and exploring for the advanced therapy of autoimmune diseases. There would be 2 products applying for marketing in 2023.

Among them, HB0025, the first bispecific fusion protein targeting PD-L1/VEGF around the world, enters clinical trials in both China and the U.S, demonstrating the strong capability of Huaota in R&D of innovative drugs. The first patient had been dosed with HB0025 in March 2021 after the approval in the United States, and the domestic clinical research has been initiated in April 2021.

At the moment when license-in has become a routine operation to enrich pipelines, Huaota adheres to the model of independent research and development, global IP, and actively seeks global cooperation. The company has been granted for "national high-tech enterprise", and in responsibility for a number of science and technology projects in Shanghai and Zhejiang, more than 20 of which has applied for domestic and international invention patents.

At Huaota, we have built a professional and sophisticated team led by Dr. Xiangyang Zhu, an expert with more than 20 years of experience in the development of macromolecular drugs, especially in developing, manufacturing and registration of biologics. Dr. Zhu had gained a great wealth of experience when he worked in Boehringer Ingelheim (BI) (USA, Germany, China), leading and involved in the research of more than 20 monoclonal or dual-target antibody projects.